Cargando…

PRMT5: An Emerging Target for Pancreatic Adenocarcinoma

SIMPLE SUMMARY: The burden of pancreatic ductal adenocarcinoma (PDAC) increases with rising incidence, yet 5-year overall survival remains poor at 17%. Routine comprehensive genomic profiling of PDAC only finds 2.5% of patients who may benefit and receive matched targeted therapy. Protein arginine m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Michael K. C., Grimmond, Sean M., McArthur, Grant A., Sheppard, Karen E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534199/ https://www.ncbi.nlm.nih.gov/pubmed/34680285 http://dx.doi.org/10.3390/cancers13205136

Ejemplares similares

PRMT5 function and targeting in cancer
por: Kim, Hyungsoo, et al.
Publicado: (2020)

Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
por: Alkaraki, Arwa, et al.
Publicado: (2021)

The therapeutic potential of targeting minimal residual disease in melanoma
por: Patel, Riyaben P, et al.
Publicado: (2023)

The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids
por: Low, Ronnie Ren Jie, et al.
Publicado: (2021)

The Role of PRMT5 in Immuno-Oncology
por: Abe, Yoshinori, et al.
Publicado: (2023)

PRMT5 is a therapeutic target in choroidal neovascularization
por: Muniyandi, Anbukkarasi, et al.
Publicado: (2023)

Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
por: AbuHammad, Shatha, et al.
Publicado: (2019)

Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia
por: Creeden, Justin F., et al.
Publicado: (2020)

PRMT1 loss sensitizes cells to PRMT5 inhibition
por: Gao, Guozhen, et al.
Publicado: (2019)

Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
por: Lelliott, Emily J., et al.
Publicado: (2021)

The Structure and Functions of PRMT5 in Human Diseases
por: Motolani, Aishat, et al.
Publicado: (2021)

PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma
por: Giuliani, Virginia, et al.
Publicado: (2021)

Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?
por: Smith, Lorey K., et al.
Publicado: (2020)

Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma
por: Huffman, Brandon M., et al.
Publicado: (2022)

PRMT5 and CDK4/6 inhibition result in distinctive patterns of alternative splicing in melanoma
por: Chan, Lok Hang, et al.
Publicado: (2023)

Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer
por: Shailesh, Harshita, et al.
Publicado: (2018)

The Emerging Role of PRMT6 in Cancer
por: Chen, Zhixian, et al.
Publicado: (2022)

Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
por: Lelliott, Emily J., et al.
Publicado: (2022)

The Methyltransferases PRMT4/CARM1 and PRMT5 Control Differentially Myogenesis in Zebrafish
por: Batut, Julie, et al.
Publicado: (2011)

The Role of the PRMT5–SND1 Axis in Hepatocellular Carcinoma
por: Wright, Tanner, et al.
Publicado: (2021)

Protein arginine methyltransferases PRMT1, PRMT4/CARM1 and PRMT5 have distinct functions in control of osteoblast differentiation
por: Dashti, Parisa, et al.
Publicado: (2023)

PRMT5 inhibitors on the (myeloma) road
por: Gulla, Annamaria, et al.
Publicado: (2018)

PRMT5 prognostic value in cancer
por: Lattouf, Hanine, et al.
Publicado: (2019)

Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma
por: Feigin, Michael E., et al.
Publicado: (2017)

Regulation of a PRMT5/NF-κB Axis by Phosphorylation of PRMT5 at Serine 15 in Colorectal Cancer
por: Hartley, Antja-Voy, et al.
Publicado: (2020)

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
por: Orben, Felix, et al.
Publicado: (2022)

MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression
por: Sun, Yan, et al.
Publicado: (2023)

PRMT5 promotes progression of endometrioid adenocarcinoma via ERα and cell cycle signaling pathways
por: Mei, Shuyu, et al.
Publicado: (2021)

PRMT5-mediated regulation of developmental myelination
por: Scaglione, Antonella, et al.
Publicado: (2018)

PRMT5 in gene regulation and hematologic malignancies
por: Zhu, Fen, et al.
Publicado: (2019)

Antitumor Effects of PRMT5 Inhibition in Sarcomas
por: Verbeke, Stéphanie, et al.
Publicado: (2023)

Structure, Activity, and Function of PRMT1
por: Thiebaut, Charlène, et al.
Publicado: (2021)

Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma
por: Ahn, Daniel H., et al.
Publicado: (2018)

PRMT5 inhibition disrupts splicing and stemness in glioblastoma
por: Sachamitr, Patty, et al.
Publicado: (2021)

Genome wide comparative analysis of the effects of PRMT5 and PRMT4/CARM1 arginine methyltransferases on the Arabidopsis thaliana transcriptome
por: Hernando, Carlos E, et al.
Publicado: (2015)

Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma
por: Roalsø, Marcus T. T., et al.
Publicado: (2022)

The Emergence of TRP Channels Interactome as a Potential Therapeutic Target in Pancreatic Ductal Adenocarcinoma
por: Wei, Yuanyuan, et al.
Publicado: (2023)

PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis
por: Qin, Yi, et al.
Publicado: (2019)

An AKT/PRMT5/SREBP1 axis in lung adenocarcinoma regulates de novo lipogenesis and tumor growth
por: Liu, Liu, et al.
Publicado: (2021)

Current and Future Therapies for Pancreatic Ductal Adenocarcinoma
por: Sally, Áine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uoao0gcntshsfjughi3m4bm5a9